Merck warns docs to stop prescribing Tredaptive

Published



Drugmaker Merck & Co. is suspending its sale of the cholesterol drug Tredaptive after initial results from a study showed that it wasn’t effective and could raise the risk of some serious side effects.

The Whitehouse Station, N.J., company said Friday it is telling doctors to quit prescribing the tablets, which are not approved in the United States, and it also is advising patients to stop taking the medication only after talking to a physician.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.